Does the media prefer CTMX or SRPT?

In the previous week, Sarepta Therapeutics had 1 more articles in the media than CytomX Therapeutics. MarketBeat recorded 3 mentions for Sarepta Therapeutics and 2 mentions for CytomX Therapeutics. Sarepta Therapeutics' average media sentiment score of 0.61 beat CytomX Therapeutics' score of -0.33 indicating that Sarepta Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sarepta Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SRPT or PTGX?

In the previous week, Protagonist Therapeutics had 1 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 4 mentions for Protagonist Therapeutics and 3 mentions for Sarepta Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.09 beat Sarepta Therapeutics' score of 0.61 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IMVT or SRPT?

In the previous week, Sarepta Therapeutics had 1 more articles in the media than Immunovant. MarketBeat recorded 3 mentions for Sarepta Therapeutics and 2 mentions for Immunovant. Immunovant's average media sentiment score of 0.79 beat Sarepta Therapeutics' score of 0.61 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sarepta Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SRPT or LNTH?

In the previous week, Lantheus had 1 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 4 mentions for Lantheus and 3 mentions for Sarepta Therapeutics. Sarepta Therapeutics' average media sentiment score of 0.61 beat Lantheus' score of 0.46 indicating that Sarepta Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Sarepta Therapeutics (SRPT) Competitors

$17.65 +0.12 (+0.68%)

Closing price 06/22/2026 04:00 PM Eastern

Extended Trading

$17.34 -0.31 (-1.76%)

As of 07:38 AM Eastern

Compare

SRPT vs. CTMX, EDIT, PTGX, IMVT, and LNTH

Should you buy Sarepta Therapeutics stock or one of its competitors? MarketBeat compares Sarepta Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sarepta Therapeutics include CytomX Therapeutics (CTMX), Editas Medicine (EDIT), Protagonist Therapeutics (PTGX), Immunovant (IMVT), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry.

How does Sarepta Therapeutics compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and Sarepta Therapeutics (NASDAQ:SRPT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

CytomX Therapeutics has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$35.54M	14.56	-$17.37M	-$0.41	N/A
Sarepta Therapeutics	$2.20B	0.85	-$713.41M	-$0.96	N/A

CytomX Therapeutics has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market.

CytomX Therapeutics presently has a consensus target price of $12.10, indicating a potential upside of 298.03%. Sarepta Therapeutics has a consensus target price of $24.81, indicating a potential upside of 40.56%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CytomX Therapeutics is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Sarepta Therapeutics	6 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.08

In the previous week, Sarepta Therapeutics had 1 more articles in the media than CytomX Therapeutics. MarketBeat recorded 3 mentions for Sarepta Therapeutics and 2 mentions for CytomX Therapeutics. Sarepta Therapeutics' average media sentiment score of 0.61 beat CytomX Therapeutics' score of -0.33 indicating that Sarepta Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sarepta Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sarepta Therapeutics has a net margin of -2.94% compared to CytomX Therapeutics' net margin of -166.40%. Sarepta Therapeutics' return on equity of 7.56% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
Sarepta Therapeutics	-2.94%	7.56%	2.94%

67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are owned by institutional investors. 3.8% of CytomX Therapeutics shares are owned by insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

CytomX Therapeutics beats Sarepta Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Sarepta Therapeutics compare to Editas Medicine?

Sarepta Therapeutics (NASDAQ:SRPT) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

Editas Medicine has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.85	-$713.41M	-$0.96	N/A
Editas Medicine	$38.69M	7.08	-$160.06M	-$1.23	N/A

Sarepta Therapeutics presently has a consensus target price of $24.81, suggesting a potential upside of 40.56%. Editas Medicine has a consensus target price of $5.40, suggesting a potential upside of 92.86%. Given Editas Medicine's stronger consensus rating and higher possible upside, analysts clearly believe Editas Medicine is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.08
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Sarepta Therapeutics has a beta of 0.21, meaning that its share price is 79% less volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.16, meaning that its share price is 116% more volatile than the broader market.

86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 6.9% of Sarepta Therapeutics shares are owned by company insiders. Comparatively, 3.1% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Sarepta Therapeutics had 3 more articles in the media than Editas Medicine. MarketBeat recorded 3 mentions for Sarepta Therapeutics and 0 mentions for Editas Medicine. Sarepta Therapeutics' average media sentiment score of 0.61 beat Editas Medicine's score of 0.00 indicating that Sarepta Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Sarepta Therapeutics	Positive
Editas Medicine	Neutral

Sarepta Therapeutics has a net margin of -2.94% compared to Editas Medicine's net margin of -281.59%. Sarepta Therapeutics' return on equity of 7.56% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-2.94%	7.56%	2.94%
Editas Medicine	-281.59%	-677.39%	-58.25%

Summary

Sarepta Therapeutics beats Editas Medicine on 10 of the 16 factors compared between the two stocks.

How does Sarepta Therapeutics compare to Protagonist Therapeutics?

Sarepta Therapeutics (NASDAQ:SRPT) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Sarepta Therapeutics has a net margin of -2.94% compared to Protagonist Therapeutics' net margin of -154.88%. Sarepta Therapeutics' return on equity of 7.56% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-2.94%	7.56%	2.94%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

Protagonist Therapeutics has lower revenue, but higher earnings than Sarepta Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.85	-$713.41M	-$0.96	N/A
Protagonist Therapeutics	$74.06M	99.88	-$130.15M	-$1.81	N/A

Sarepta Therapeutics has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.86, meaning that its stock price is 86% more volatile than the broader market.

Sarepta Therapeutics presently has a consensus price target of $24.81, suggesting a potential upside of 40.56%. Protagonist Therapeutics has a consensus price target of $115.21, suggesting a potential upside of 0.16%. Given Sarepta Therapeutics' higher probable upside, research analysts plainly believe Sarepta Therapeutics is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.08
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Protagonist Therapeutics had 1 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 4 mentions for Protagonist Therapeutics and 3 mentions for Sarepta Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.09 beat Sarepta Therapeutics' score of 0.61 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

86.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 6.9% of Sarepta Therapeutics shares are held by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Protagonist Therapeutics beats Sarepta Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Sarepta Therapeutics compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

Immunovant has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market.

In the previous week, Sarepta Therapeutics had 1 more articles in the media than Immunovant. MarketBeat recorded 3 mentions for Sarepta Therapeutics and 2 mentions for Immunovant. Immunovant's average media sentiment score of 0.79 beat Sarepta Therapeutics' score of 0.61 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sarepta Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are owned by institutional investors. 1.8% of Immunovant shares are owned by company insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Immunovant has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -2.94%. Sarepta Therapeutics' return on equity of 7.56% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Sarepta Therapeutics	-2.94%	7.56%	2.94%

Immunovant presently has a consensus price target of $37.33, indicating a potential downside of 2.01%. Sarepta Therapeutics has a consensus price target of $24.81, indicating a potential upside of 40.56%. Given Sarepta Therapeutics' higher possible upside, analysts plainly believe Sarepta Therapeutics is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Sarepta Therapeutics	6 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.08

Immunovant has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Sarepta Therapeutics	$2.20B	0.85	-$713.41M	-$0.96	N/A

Summary

Sarepta Therapeutics beats Immunovant on 9 of the 15 factors compared between the two stocks.

How does Sarepta Therapeutics compare to Lantheus?

Sarepta Therapeutics (NASDAQ:SRPT) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

In the previous week, Lantheus had 1 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 4 mentions for Lantheus and 3 mentions for Sarepta Therapeutics. Sarepta Therapeutics' average media sentiment score of 0.61 beat Lantheus' score of 0.46 indicating that Sarepta Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sarepta Therapeutics currently has a consensus target price of $24.81, suggesting a potential upside of 40.56%. Lantheus has a consensus target price of $101.86, suggesting a potential downside of 4.09%. Given Sarepta Therapeutics' higher probable upside, equities analysts plainly believe Sarepta Therapeutics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.08
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Sarepta Therapeutics has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, suggesting that its share price is 103% less volatile than the broader market.

Lantheus has a net margin of 18.05% compared to Sarepta Therapeutics' net margin of -2.94%. Lantheus' return on equity of 29.32% beat Sarepta Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-2.94%	7.56%	2.94%
Lantheus	18.05%	29.32%	15.00%

Lantheus has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.85	-$713.41M	-$0.96	N/A
Lantheus	$1.55B	4.47	$233.56M	$4.15	25.59

86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 6.9% of Sarepta Therapeutics shares are owned by company insiders. Comparatively, 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Lantheus beats Sarepta Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Sarepta Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SRPT vs. The Competition

Export

Metric	Sarepta Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.85B	$3.41B	$6.42B	$12.54B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	-18.39	19.52	24.71	24.33
Price / Sales	0.85	330.35	520.96	110.57
Price / Cash	N/A	56.54	27.92	37.84
Price / Book	1.62	8.34	10.77	6.58
Net Income	-$713.41M	$23.80M	$3.56B	$336.75M
7 Day Performance	11.85%	4.61%	1.19%	0.12%
1 Month Performance	5.06%	1.75%	0.00%	1.45%
1 Year Performance	-6.47%	59.74%	31.92%	33.66%

Sarepta Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SRPT Sarepta Therapeutics	3.0085 of 5 stars	$17.65 +0.7%	$24.81 +40.6%	-12.1%	$1.85B	$2.20B	N/A	1,372
CTMX CytomX Therapeutics	2.6684 of 5 stars	$3.04 +3.1%	$12.10 +298.0%	+31.0%	$502.05M	$76.20M	N/A	170
EDIT Editas Medicine	2.4697 of 5 stars	$2.80 +4.1%	$5.40 +92.9%	+26.1%	$263.37M	$40.52M	N/A	230
PTGX Protagonist Therapeutics	1.3856 of 5 stars	$115.03 +1.9%	$115.21 +0.2%	+115.7%	$7.26B	$46.02M	N/A	120	Positive News
IMVT Immunovant	1.7846 of 5 stars	$38.10 +7.8%	$37.33 -2.0%	+141.1%	$7.26B	N/A	N/A	120	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SRPT) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sarepta Therapeutics (SRPT) Competitors

SRPT vs. CTMX, EDIT, PTGX, IMVT, and LNTH

How does Sarepta Therapeutics compare to CytomX Therapeutics?

Summary

How does Sarepta Therapeutics compare to Editas Medicine?

Summary

How does Sarepta Therapeutics compare to Protagonist Therapeutics?

Summary

How does Sarepta Therapeutics compare to Immunovant?

Summary

How does Sarepta Therapeutics compare to Lantheus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRPT vs. The Competition

Sarepta Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sarepta Therapeutics (SRPT) Competitors

SRPT vs. CTMX, EDIT, PTGX, IMVT, and LNTH

How does Sarepta Therapeutics compare to CytomX Therapeutics?

Which has preferable valuation and earnings, CTMX or SRPT?

Which has more volatility and risk, CTMX or SRPT?

Do analysts prefer CTMX or SRPT?

Does the media prefer CTMX or SRPT?

Is CTMX or SRPT more profitable?

Do institutionals & insiders believe in CTMX or SRPT?

Summary

How does Sarepta Therapeutics compare to Editas Medicine?

Which has preferable earnings and valuation, SRPT or EDIT?

Do analysts recommend SRPT or EDIT?

Which has more risk & volatility, SRPT or EDIT?

Do institutionals & insiders hold more shares of SRPT or EDIT?

Does the media favor SRPT or EDIT?

Is SRPT or EDIT more profitable?

Summary

How does Sarepta Therapeutics compare to Protagonist Therapeutics?

Is SRPT or PTGX more profitable?

Which has stronger valuation and earnings, SRPT or PTGX?

Which has more volatility & risk, SRPT or PTGX?

Do analysts recommend SRPT or PTGX?

Does the media favor SRPT or PTGX?

Do institutionals and insiders hold more shares of SRPT or PTGX?

Summary

How does Sarepta Therapeutics compare to Immunovant?

Which has more risk and volatility, IMVT or SRPT?

Does the media refer more to IMVT or SRPT?

Do insiders & institutionals hold more shares of IMVT or SRPT?

Is IMVT or SRPT more profitable?

Do analysts prefer IMVT or SRPT?

Which has preferable earnings & valuation, IMVT or SRPT?

Summary

How does Sarepta Therapeutics compare to Lantheus?

Does the media favor SRPT or LNTH?

Do analysts recommend SRPT or LNTH?

Which has more volatility and risk, SRPT or LNTH?

Is SRPT or LNTH more profitable?

Which has higher valuation and earnings, SRPT or LNTH?

Do institutionals & insiders have more ownership in SRPT or LNTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRPT vs. The Competition

Sarepta Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools